1. A recombinant vector comprising a DNA segment which encodes a recombinant protein that has the following sequences: an amino acid sequence with at least 90% amino acid sequence identity to residue 1 to residue 40 of a wild-type EBNA-1 protein of Epstein-Barr virus (EBV) having SEQ ID NO:1 which is N-terminal to at least three consecutive tripeptides selected from any combination of the following tripeptides Gly-Gly-Ala, Gly-Ala-Gly, Gly-Gly-Gly, Ala-Gly-Ala, or Ala-Gly-Gly, which are N-terminal to an amino acid sequence with at least 90% amino acid sequence identity to residues 328 to 641 of SEQ ID NO:1, wherein the recombinant protein lacks residues 65 to 89 of the wild-type EBNA-1 protein, wherein the recombinant protein binds an oriP of EBV with an affinity that is at least 10% that of the binding of the wild-type EBNA-1 protein, is noncytotoxic and activates transcription at levels at least 5% that of the wild-type EBNA-1 protein from an extrachromosomal template having an oriP of EBV which is capable of binding the wild-type EBNA-1 protein.
2. The recombinant vector of claim 1 wherein the DNA segment comprises a first DNA fragment encoding residues 1 to 40 of the wild-type EBNA-1 protein and a second DNA fragment encoding residues from residue 328 to the C-terminal residue of the wild-type EBNA-1 protein.
3. The recombinant vector of claim 2 wherein the DNA segment further comprises a third DNA fragment inserted between the first and second DNA fragments, which third DNA fragment comprises a portion of an open reading frame.
4. The recombinant vector of claim 3 wherein the third DNA fragment encodes LR2 of the wild-type EBNA-1 protein.
5. The recombinant vector of claim 1 further comprising the DNA sequence having oriP of EBV.
6. The recombinant vector of claim 5 further comprising a heterologous open reading frame.
7. The recombinant vector of claim 6 wherein the heterologous open reading frame is operably linked to a transcriptional regulatory element.
8. The recombinant vector of claim 7 wherein the transcriptional regulatory element is a promoter.
9. The recombinant vector of claim 7 wherein the transcriptional regulatory element includes an enhancer.
10. The recombinant vector of claim 6 wherein the heterologous open reading frame encodes a therapeutic or prophylactic gene product.
11. The recombinant vector of claim 1 or 10 further comprising a selectable gene or a marker gene.
12. The recombinant vector of claim 1 which encodes a recombinant protein with at least 95% amino acid sequence identity to residues 1 to 40 and to residues 328 to 641 of SEQ ID NO:1.
13. The recombinant vector of claim 1 which comprises the Gly-Gly-Ala repeat region of the wild-type EBNA-1 protein.
14. The recombinant vector of claim 1 wherein the recombinant protein activates transcription from the extracbromosomal template at levels at least 10% that of the wild-type EBNA-1 protein.
15. The recombinant vector of claim 1 which is a plasmid.
16. The recombinant vector of claim 1 which is a recombinant virus.
17. The recombinant vector of claim 1 wherein the amino acid sequence with at least 90% amino acid sequence identity to residues 328 to 641 of SEQ ID NO:1 has a wild-type EBNA-1 nuclear localization sequence.
18. A derivative encoded by the recombinant vector of claim 1.
19. A method to maintain and express a heterologous open reading frame in a cell, comprising contacting a cell with a recombinant plasmid comprising the heterologous open reading frame and a DNA sequence which is capable of binding a wild-type EBNA-1 protein with an affinity that is at least 10% that of an oriP of EBV, which cell expresses a DNA segment which encodes a recombinant protein, wherein the recombinant protein has the following sequences: an amino acid sequence with at least 90% amino acid sequence identity to residue 1 to residue 40 of a wild-type EBNA-1 protein of EBV having SEQ ID NO:1 which is N-terminal to at least three consecutive tripeptides selected from any combination of the following tripeptides Gly-Gly-Ala, Gly-Ala-Gly, Gly-Gly-Gly, Ala-Gly-Ala, or Ala-Gly-Gly, which are N-terminal to an amino acid sequence with at least 90% amino acid sequence identity to residues 328 to 641 of SEQ ID NO:1, wherein the recombinant protein lacks residues 65 to 89 of the wild-type EBNA-1 protein, wherein the recombinant protein binds an oriP of EBV with an affinity that is at least 10% that of the binding of the wild-type EBNA-1 protein, is noncytotoxic, and activates transcription at levels at least 5% that of the wild-type EBNA-1 protein from an extrachromosomal template having an oriP of EBV which is capable of binding the wild-type EBNA-1 protein.
20. A method to maintain and express a heterologous open reading frame in a cell, comprising contacting a cell with a recombinant plasmid comprising the heterologous open reading frame and a DNA sequence which is capable of binding a wild-type EBNA-1 protein with an affinity that is at least 10% that of an oriP of EBV, and a DNA segment which encodes a recombinant protein, wherein the recombinant protein has the following sequences: an amino acid sequence with at least 90% amino acid sequence identity to residue 1 to residue 40 of a wild-type EBNA-1 protein of EBV having SEQ ID NO:1 that is N-terminal to at least three consecutive tripeptides selected from any combination of the following tripeptides Gly-Gly-Ala, Gly-Ala-Gly, Gly-Gly-Gly, Ala-Gly-Ala, or Ala-Gly-Gly, which are N-terminal to an amino acid sequence with at least 90% amino acid sequence identity to residues 328 to 641 of SEQ ID NO:1, wherein the recombinant protein lacks residues 65 to 89 of the wild-type EBNA-1 protein, wherein the recombinant protein binds an oriP of EBV with an affinity that is at least 10% that of the binding of the wild-type EBNA-1 protein, is noncytotoxic. and activates transcription at levels at least 5% that of the wild-type EBNA-1 protein from an extrachromosomal template having an oriP of EBV which is capable of binding the wild-type EBNA-1 protein.
21. The method of claim 19 wherein the DNA segment is on a second recombinant plasmid.
22. The method of claim 19 or 20 wherein the heterologous open reading frame encodes a therapeutic or prophylactic gene product.
23. The method of claim 19 or 20 wherein the heterologous open reading frame is operably linked to a promoter to form an expression cassette.
24. The method of claim 19 or 20 wherein the recombinant protein activates transcription from the plasmid at levels at least 10% that of the corresponding wild-type protein.
25. The method of claim 19 or 20 wherein the cell is a cultured or primary cell.
26. The method of claim 25 wherein the cell is a mammalian cell.
27. The method of claim 19 or 20 wherein a mammal is contacted with the recombinant plasmid.
28. A recombinant vector comprising:
a DNA segment which encodes a recombinant protein that is noncytotoxic relative to a wild-type EBNA-1 protein having SEQ ID NO:1, which recombinant protein has the following sequences: an amino acid sequence with at least 90% amino acid sequence identity to residue 1 to residue 40 of a wild-type EBNA-1 protein of EBV having SEQ ID NO:1 that is N-terminal to at least three consecutive tripeptides selected from any combination of the following tripeptides Gly-Gly-Ala, Gly-Ala-Gly, Gly-Gly-Gly, Ala-Gly-Ala, or Ala-Gly-Gly, which are N-terminal to an amino acid sequence with at least 90% amino acid sequence identity to residues 328 to 641 of SEQ ID NO:1, wherein the recombinant protein lacks residues 65 to 89 of the wild-type EBNA-1 protein, wherein the recombinant protein binds an oriP of EBV with an affinity that is at least 10% that of the wild-type EBNA-1 protein, and activates transcription at levels at least 5% that of the wild-type EBNA-1 protein from an extrachromosomal template having an oriP of EBV which is capable of binding the wild-type EBNA-1 protein;
the DNA sequence which binds the wild-type protein; and
a DNA fragment with a multiple cloning site sequence 3\u2032 to a promoter.
29. The vector of claim 28 further comprising a heterologous open reading frame inserted into a cloning site in the multiple cloning site sequence.
30. The recombinant vector of claim 28 which encodes a recombinant protein with at least 95% amino acid sequence identity to residues 1 to 40 and residues 328 to 641, and lacks residues about 65 to 89, of the wild-type EBNA-1 protein having SEQ ID NO:1.
31. The recombinant vector of claim 1 which encodes a recombinant protein having at least 90% amino acid sequence identity to residues 1 to 64 and residues 90 to 641 of SEQ ID NO:1.
32. The recombinant vector of claim 31 which encodes a recombinant protein having residues 1 to 64 and residues 90 to 641 of SEQ lD NO:1.
33. The method of claim 19 or 20 wherein the recombinant protein has at least 90% amino acid sequence identity to residues 1 to 64 and residues 90 to 641 of SEQ lD NO:1.
34. The method of claim 33 wherein the recombinant protein has residues 1 to 64 and residues 90 to 641 of SEQ lD NO:1.
35. The vector of claim 28 wherein the recombinant protein has at least 90% amino acid sequence identity to residues 1 to 64 and residues 90 to 641 of SEQ ID NO:1.
36. The vector of claim 35 wherein the recombinant protein has residues 1 to 64 and residues 90 to 641 of SEQ ID NO:1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A data processing method, comprising the steps of:
(a) initializing a syndrome vector to be an (n\u22121)th symbol;
(b) finding a corresponding mask based on the syndrome vector, wherein a value of the mask is equal to 0 when a value of the (n\u22121)th symbol is equal to 0;
(c) correcting a known constant based on the mask, wherein a value of the known constant corrected based on the mask is equal to 0 when a value of the syndrome vector is equal to 0;
(d) inputting the syndrome vector to a log look-up table to correspondingly find log data;
(e) performing, based on the log data and a log known constant, a modulo addition operation corresponding to log maximum data to find a log sum; and
(f) inputting the log sum to an anti-log look-up table to correspondingly find operational data.
2. The method according to claim 1, further comprising the steps of:
(g) summating the operational data and an (n\u22122)th symbol to find currently summated data;
(h) judging whether the (n\u22122)th symbol is a last symbol or not; and
(i) outputting the currently summated data as the syndrome vector when the (n\u22122)th symbol is the last symbol.
3. The method according to claim 2, wherein when the (n\u22122)th symbol is not the last symbol, the currently summated data serves as the syndrome vector and the steps (b) to (h) are repeatedly performed.
4. The method according to claim 1, wherein in the step (d), the log data having a value equal to 0 is corresponding found according to the log look-up table when the value of the syndrome vector is equal to 0.
5. The method according to claim 4, wherein the log data and the syndrome vector satisfy the equation:
S2=log(S1)+1,
wherein S1 and S2 are the syndrome vector inputted to the log look-up table and the log data corresponding found according to the log look-up table, respectively.
6. The method according to claim 1, wherein in the step (f), the operational data having a value equal to 0 is correspondingly found according to the anti-log look-up table when the log sum is equal to 1.
7. The method according to claim 1 being applied to a syndrome operation of a Reed-Solomon code.
8. The method according to claim 1, wherein in the step (b), the mask is equal to a maximum data value when the syndrome vector is not equal to 0.
9. The method according to claim 1, wherein in the step (c), the known constant is corrected by performing an AND operation according to the mask and the known constant.
10. A computer system medium having a computer-executable instruction for performing a data processing method, the data processing method comprising the steps of:
(a) initializing a syndrome vector to be an (n\u22121)th symbol;
(b) finding a corresponding mask according to the syndrome vector, wherein a value of the mask is equal to 0 when a value of the (n\u22121)th symbol is equal to 0;
(c) correcting a known constant based on the mask, wherein a value of the known constant corrected based on the mask is equal to 0 when a value of the syndrome vector is equal to 0;
(d) inputting the syndrome vector to a log look-up table to correspondingly find log data;
(e) performing, based on the log data and a log known constant, a modulo addition operation corresponding to log maximum data to find a log sum; and
(f) inputting the log sum to an anti-log look-up table to correspondingly find operational data.
11. The medium according to claim 10, wherein the data processing method further comprises the steps of:
(g) summating the operational data and an (n\u22122)th symbol to find currently summated data;
(h) judging whether the (n\u22122)th symbol is a last symbol or not; and
(i) outputting the currently summated data as the syndrome vector when the (n\u22122)th symbol is the last symbol.
12. The medium according to claim 11, wherein when the (n\u22122)th symbol is not the last symbol, the currently summated data serves as the syndrome vector and the steps (b) to (h) are repeatedly performed.
13. The medium according to claim 10, wherein in the step (d), the log data having a value equal to 0 is corresponding found according to the log look-up table when the value of the syndrome vector is equal to 0.
14. The medium according to claim 13, wherein the log data and the syndrome vector satisfy the equation:
S2=log(S1)+1,
wherein S1 and S2 are the syndrome vector inputted to the log look-up table and the log data corresponding found according to the log look-up table, respectively.
15. The medium according to claim 10, wherein in the step (f), the operational data having a value equal to 0 is correspondingly found according to the anti-log look-up table when the log sum is equal to 1.
16. The medium according to claim 10, wherein the data processing method is applied to a syndrome operation of a Reed-Solomon code.
17. The medium according to claim 10, wherein in the step (b) of the data processing method, the mask is equal to a maximum data value when the syndrome vector is not equal to 0.
18. The medium according to claim 10, wherein in the step (c), the known constant is corrected by performing an AND operation according to the mask and the known constant.
19. The medium according to claim 10 being applied to a computer system having a vectorization parallel processing instruction set, wherein the computer system performs the steps (a) to (f) of the data processing method on the symbols in response to instructions of the vectorization parallel processing instruction set.